Amgen Inc (AMG) Stock Price & News

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia

About Amgen Inc

CEORobert A. Bradway

Employees၃.၁၅ သောင်း

Founded၁၉၈၀

Headquartersသောင်စင်အုက်စ်, ကယ်လီဖိုးနီးယားပြည်နယ်, ယူနိုက်တက်စတိတ်

SectorHealth Care

Industry-

Websiteamgen.com

Revenue

Net income

All values in USD	၂၀၂၅ ဒီ	၂၀၂၆ မတ်	၂၀၂၆ ဇွန်	၂၀၂၆ စက်
Revenue	၉၈၆.၆၀ ဋေ	၈၆၁.၈၀ ဋေ	ဋေ ၁.၀၁ ထ	ဋေ ၁.၀၄ ထ
Cost of goods sold	၂၆၇.၆၀ ဋေ	၂၄၉.၇၀ ဋေ	၂၇၅.၁၀ ဋေ	၂၇၈.၈၀ ဋေ
Cost of revenue	၂၆၇.၆၀ ဋေ	၂၄၉.၇၀ ဋေ	၂၇၅.၁၀ ဋေ	၂၇၈.၈၀ ဋေ
Research and development expenses	၂၁၄.၂၀ ဋေ	၁၇၁.၉၀ ဋေ	၁၈၆.၈၀ ဋေ	၂၁၁.၁၀ ဋေ
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	၁၉၅.၂၀ ဋေ	၁၆၀.၂၀ ဋေ	၁၇၄.၅၀ ဋေ	၁၆၈.၀၀ ဋေ
Operating expense	၄၁၇.၆၀ ဋေ	၃၂၀.၈၀ ဋေ	၃၇၂.၉၀ ဋေ	၃၈၆.၇၀ ဋေ
Total operating expenses	၆၈၅.၂၀ ဋေ	၅၇၀.၅၀ ဋေ	၆၄၈.၀၀ ဋေ	၆၆၅.၅၀ ဋေ
Operating income	၃၀၁.၄၀ ဋေ	၂၉၁.၃၀ ဋေ	၃၅၇.၄၀ ဋေ	၃၇၁.၀၀ ဋေ
Other non operating income	၁၄.၃၀ ကုဋေ	၁၉.၂၀ ကုဋေ	၁၄.၅၀ ကုဋေ	၁၂.၇၀ ကုဋေ
EBT including unusual items	၁၅၁.၄၀ ဋေ	၂၀၈.၄၀ ဋေ	၂၇၆.၈၀ ဋေ	၄၆၈.၆၀ ဋေ
EBT excluding unusual items	၂၅၀.၉၀ ဋေ	၂၃၇.၁၀ ဋေ	၃၀၅.၅၀ ဋေ	၃၁၈.၆၀ ဋေ
Income tax expense	၁၈.၁၀ ကုဋေ	၂၆.၅၀ ကုဋေ	၃၉.၃၀ ကုဋေ	၈၂.၂၀ ကုဋေ
Effective tax rate	၁၁.၉၆%	၁၂.၇၂%	၁၄.၂၀%	၁၇.၅၄%
Other operating expenses	၈.၂၀ ကုဋေ	-၁၁.၃၀ ကုဋေ	၁၁.၆၀ ကုဋေ	၇.၆၀ ကုဋေ
Net income	၁၃၃.၃၀ ဋေ	၁၈၁.၉၀ ဋေ	၂၃၇.၅၀ ဋေ	၃၈၆.၄၀ ဋေ
Net profit margin	၁၃.၅၁%	၂၁.၁၁%	၂၃.၆၂%	၃၇.၂၈%
Earnings per share	၅.၂၉	၅.၁၅	၆.၂၉	၆.၄၅
Interest and investment income	၄၀.၈၀ ကုဋေ	-	-	-
Interest expense	-၁၀၆.၁၀ ဋေ	-၆၅.၇၀ ကုဋေ	-၆၇.၃၀ ကုဋေ	-၆၅.၃၀ ကုဋေ
Net interest expenses	-၆၅.၃၀ ကုဋေ	-၆၅.၇၀ ကုဋေ	-၆၇.၃၀ ကုဋေ	-၆၅.၃၀ ကုဋေ
Depreciation and amortization charges	-	-	-	-
EBITDA	၄၀၂.၂၀ ဋေ	၄၀၂.၉၀ ဋေ	၄၆၈.၆၀ ဋေ	၄၈၃.၂၀ ဋေ
Gain or loss from assets sale	-	-	-	-

Ask anything